Company announcement no 2026-05 | 5 March 2026 |
Decisions of annual general meeting
Today, Demant A/S held its annual general meeting at the company’s premises, Kongebakken 9, 2765 Smørum, Denmark.
In his address, the Chair of the Board of Directors, Niels B. Christiansen, gave an account of the Group’s development in 2025. The report is available on www.demant.com. He said among other things:
“In line with the revised expectations, the Group achieved organic growth of 2% and an operating profit before special items of DKK 3.96 billion. These results were achieved in a market characterised by continuously intense competition and a slowdown in the demand for hearing aids. Given these circumstances, it is particularly important that Demant stays on course, maintains its focus on long-term value creation and continues to execute its strategy. Two crucial milestones during the year were the completion of our largest expansion ever: the acquisition of German KIND and the launch of the discreet and uncompromising hearing aid, Oticon Zeal.”
Niels B. Christiansen also alluded to his departure from the Board of Directors and emphasised the important results achieved by the company during his tenure:
“For almost two decades, I have had the pleasure of following Demant’s development closely – a journey marked by significant growth and value creation, continuous innovation and an unwavering focus on improving the lives of people with hearing loss. Revenue has grown from around DKK 5 billion to an expected more than DKK 25 billion this year, and the organisation has grown from employing about 5,000 people to now employing more than 26,000 people globally. Over the years, we have experienced periods with very solid results, but we have also faced a few years where external conditions placed greater demands on our adaptability. Both scenarios have, however, contributed to shaping the solid and internationally competitive company that Demant is today.”
All proposals put forward by the Board of Directors were adopted by the general meeting, implying among others the following decisions:
After the general meeting, the Board of Directors elected Kristian Villumsen Chair and Niels Jacobsen Vice Chair of the Board. Sisse Fjelsted Rasmussen continues as chair of the audit committee.
Pursuant to rule 3.8.1 in Nasdaq’s Nordic Main Market Rulebook for Issuers of Shares, Demant hereby provides the following information as follow-up on the Executive Board’s share-based programme, which is part of the Executive Board’s remuneration:
Description of the | A long-term incentive programme in the form of restricted stock units (RSUs), which will be converted into shares in the company on a 1:1 ratio at vesting. Please refer to the Remuneration Policy for a detailed description of the programme. |
Vesting period | 2026-2029, i.e. three years |
Performance period | 2026, i.e. one year |
Share price used for grant calculation | DKK 188.56, i.e. the average share price quoted on Nasdaq Copenhagen of the first five trading days following publication of Demant’s Annual Report 2025. |
Total number of RSUs granted | 101,992 |
Theoretical market value of the programme | DKK 19,231,612 based on the share price used for grant calculation. The amount represents the maximum payout to be adjusted based on performance criteria. |
Further information: Søren Nielsen, President & CEO Phone +45 3917 7300 | Other contacts: René Schneider, CFO Peter Pudselykke, Head of Investor Relations Maribel Alonso Francisco, Communication Manager |
Demant is a world-leading hearing healthcare group that offers innovative technologies, solutions and expertise to help people hear better. In every aspect, from hearing care and hearing aids to diagnostic equipment and services, Demant is active and engaged. Headquartered in Denmark, the Group employs more than 22,000 people globally and is present with solutions in 130 countries creating life-changing differences through hearing health. William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks.